GU-01: Glycyrrhizin in Prostate Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Illinois at Chicago
Study ID
NCT06378346
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Observation — OTHER
    Participants will not receive glycyrrhizin
  • Glycyrrhizin - 75 mg — DRUG
    Participants will either receive 75 mg orally daily
  • Glycyrrhizin - 150 mg — DRUG
    Participants will receive 150 mg orally daily

Study Details

This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)

Key Dates

Start date
Jul 25, 2024
Status verified
Feb 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Observational Arm 1 (Dose Level 0)
    10 participants will be randomized to observational arm
  • Experimental: Glycyrrhizin Arm 2 (Dose Level 1)
    25 participants will be randomized to receive 75mg daily for 5 weeks (+/- 2 weeks)
  • Experimental: Glycyrrhizin Arm 3 (Dose Level 2)
    25 participants will be randomized to receive 150mg daily for 5 weeks (+/- 2 weeks)

Primary Outcome Measure

To evaluate anti-tumor activity of GLY by assessing changes in prostate-specific antigen (PSA) after GLY treatment administration and prior to radical prostatectomy [ Time Frame: 2 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of IllinoisChicagoIllinois60612
Natalie Reizine, MD
[email protected]
312-996-1581
Omer Qazi, MBBS
[email protected]
312-413-1069

Find similar trials in Chicago, IL

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
University of Illinois· Chicago, IL

Related Studies